Our observations in HH cells led us to hypothesize that, similar to other types of hematological and non-hematological cancers [38,39], at least some CTCL tumors may use eATP to activate purinergic receptor calcium signaling and stimulate their own growth and proliferation. This evidence concerns the gene P2RX7 and hematopoietic and lymphoid cell neoplasm.